Your browser doesn't support javascript.
loading
Human KCNQ5 de novo mutations underlie epilepsy and intellectual disability.
Wei, Aguan D; Wakenight, Paul; Zwingman, Theresa A; Bard, Angela M; Sahai, Nikhil; Willemsen, Marjolein H; Schelhaas, Helenius J; Stegmann, Alexander P A; Verhoeven, Judith S; de Man, Stella A; Wessels, Marja W; Kleefstra, Tjitske; Shinde, Deepali N; Helbig, Katherine L; Basinger, Alice; Wagner, Victoria F; Rodriguez-Buritica, David; Bryant, Emily; Millichap, John J; Millen, Kathleen J; Dobyns, William B; Ramirez, Jan-Marino; Kalume, Franck K.
Afiliação
  • Wei AD; Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington.
  • Wakenight P; Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington.
  • Zwingman TA; Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington.
  • Bard AM; Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington.
  • Sahai N; Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington.
  • Willemsen MH; Department of Human Genetics and Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Schelhaas HJ; Department of Human Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Stegmann APA; Department of Neurology, Academic Centre for Epileptology Kempenhaeghe, Heeze, The Netherlands.
  • Verhoeven JS; Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • de Man SA; Department of Neurology, Academic Centre for Epileptology Kempenhaeghe, Heeze, The Netherlands.
  • Wessels MW; Department of Pediatrics, Amphia Hospital, Breda, The Netherlands.
  • Kleefstra T; Department of Human Genetics, Erasmus Medical Centre, Rotterdam, The Netherlands.
  • Shinde DN; Department of Human Genetics, Erasmus Medical Centre, Rotterdam, The Netherlands.
  • Helbig KL; Department of Human Genetics and Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Basinger A; Ambry Genetics, Aliso Viejo, California.
  • Wagner VF; Ambry Genetics, Aliso Viejo, California.
  • Rodriguez-Buritica D; Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Bryant E; Medical Genetics, Cook Children's Hospital, Fort Worth, Texas.
  • Millichap JJ; Department of Pediatrics, University of Texas Health Science Center, Houston, Texas.
  • Millen KJ; Department of Pediatrics, University of Texas Health Science Center, Houston, Texas.
  • Dobyns WB; Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Ramirez JM; Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Kalume FK; Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
J Neurophysiol ; 128(1): 40-61, 2022 07 01.
Article em En | MEDLINE | ID: mdl-35583973
ABSTRACT
We identified six novel de novo human KCNQ5 variants in children with motor/language delay, intellectual disability (ID), and/or epilepsy by whole exome sequencing. These variants, comprising two nonsense and four missense alterations, were functionally characterized by electrophysiology in HEK293/CHO cells, together with four previously reported KCNQ5 missense variants (Lehman A, Thouta S, Mancini GM, Naidu S, van Slegtenhorst M, McWalter K, Person R, Mwenifumbo J, Salvarinova R; CAUSES Study; EPGEN Study; Guella I, McKenzie MB, Datta A, Connolly MB, Kalkhoran SM, Poburko D, Friedman JM, Farrer MJ, Demos M, Desai S, Claydon T. Am J Hum Genet 101 65-74, 2017). Surprisingly, all eight missense variants resulted in gain of function (GOF) due to hyperpolarized voltage dependence of activation or slowed deactivation kinetics, whereas the two nonsense variants were confirmed to be loss of function (LOF). One severe GOF allele (P369T) was tested and found to extend a dominant GOF effect to heteromeric KCNQ5/3 channels. Clinical presentations were associated with altered KCNQ5 channel gating milder presentations with LOF or smaller GOF shifts in voltage dependence [change in voltage at half-maximal conduction (ΔV50) = ∼-15 mV] and severe presentations with larger GOF shifts in voltage dependence (ΔV50 = ∼-30 mV). To examine LOF pathogenicity, two Kcnq5 LOF mouse lines were created with CRISPR/Cas9. Both lines exhibited handling- and thermal-induced seizures and abnormal cortical EEGs consistent with epileptiform activity. Our study thus provides evidence for in vivo KCNQ5 LOF pathogenicity and strengthens the contribution of both LOF and GOF mutations to global pediatric neurological impairment, including ID/epilepsy.NEW & NOTEWORTHY Six novel de novo human KCNQ5 variants were identified from children with neurodevelopmental delay, intellectual disability, and/or epilepsy. Expression of these variants along with four previously reported KCNQ5 variants from a similar cohort revealed GOF potassium channels, negatively shifted in V50 of activation and/or delayed deactivation kinetics. GOF is extended to KCNQ5/3 heteromeric channels, making these the predominant channels affected in heterozygous de novo patients. Kcnq5 LOF mice exhibited seizures, consistent with in vivo pathogenicity.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Epilepsia / Deficiência Intelectual Limite: Animals / Child / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Epilepsia / Deficiência Intelectual Limite: Animals / Child / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article